+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North America Viral Vector Production Market Size, Share & Trends Analysis Report By Type (Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others), By Indication, By Application, By Country and Growth Forecast, 2023 - 2030

  • PDF Icon

    Report

  • January 2024
  • Region: North America
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5935470
The North America Viral Vector Production Market would witness market growth of 18% CAGR during the forecast period (2023-2030).

Gene therapy involves introducing, altering, or replacing genes to treat or prevent diseases. Viral vectors are pivotal in delivering therapeutic genes into target cells, addressing genetic disorders, and offering potential cures for previously incurable conditions. For example, lentiviral vectors have shown assurance in feasting genetic disorders like sickle cell anemia and beta-thalassemia. Viral vectors enhance the immune system's ability to target and destroy cancer cells in cancer treatment. Oncolytic viruses, for instance, are designed to infect and destroy cancer cells while limiting healthy tissues selectively. This application shows promise in various cancer types and is under active research and development.

Viral vectors play a crucial role in neuroscience research by facilitating the delivery of genes into the central nervous system. This enables the study of neuronal function, neurodegenerative diseases, and the development of potential therapies for conditions like Parkinson's and Alzheimer's disease. As the demand for viral vectors escalates, there is a growing emphasis on optimizing production processes to achieve scalability and cost-effectiveness. Innovations in bioprocessing technologies, such as single-use systems and high-density cell culture platforms, are streamlining the manufacturing of viral vectors, ensuring a robust and reliable supply chain.

North America, particularly the United States, is a biopharmaceutical research and development hub. The region sees substantial investments from both public and private sectors in developing advanced therapies, including gene therapies and vaccines, boosting the demand for viral vectors. North America has a well-established biotechnology and pharmaceutical infrastructure, with numerous companies specializing in viral vector production. Thus, the above aspects will expand the market growth across the region in the upcoming years.

The US market dominated the North America Viral Vector Production Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,164.5 Million by 2030. The Canada market is experiencing a CAGR of 20.6% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 19.6% during (2023 - 2030).

Based on Type, the market is segmented into Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others. Based on Indication, the market is segmented into Cancer, Genetic Disorders, Infectious Diseases, and Others. Based on Application, the market is segmented into Gene Therapy, and Vaccinology. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

  • Andelyn Biosciences, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • FinVector Oy (Ferring Ventures S/A)
  • Thermo Fisher Scientific, Inc.
  • Novartis AG
  • Takara Bio Inc. (Takara Holdings Inc.)
  • Avid Bioservices, Inc.
  • Oxford Biomedica plc
  • Lonza Group Ltd.

Market Report Segmentation

By Type
  • Adeno-Associated Viral Vectors
  • Lentiviral Vectors
  • Adenoviral Vectors
  • Retroviral Vectors
  • Others
By Indication
  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others
By Application
  • Gene Therapy
  • Vaccinology
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Viral Vector Production Market, by Type
1.4.2 North America Viral Vector Production Market, by Indication
1.4.3 North America Viral Vector Production Market, by Application
1.4.4 North America Viral Vector Production Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Strategies Deployed in Viral Vector Production Market
Chapter 5. North America Viral Vector Production Market, by Type
5.1 North America Adeno-Associated Viral Vectors Market, by Country
5.2 North America Lentiviral Vectors Market, by Country
5.3 North America Adenoviral Vectors Market, by Country
5.4 North America Retroviral Vectors Market, by Country
5.5 North America Others Market, by Country
Chapter 6. North America Viral Vector Production Market, by Indication
6.1 North America Cancer Market, by Country
6.2 North America Genetic Disorders Market, by Country
6.3 North America Infectious Diseases Market, by Country
6.4 North America Others Market, by Country
Chapter 7. North America Viral Vector Production Market, by Application
7.1 North America Gene Therapy Market, by Country
7.2 North America Vaccinology Market, by Country
Chapter 8. North America Viral Vector Production Market, by Country
8.1 US Viral Vector Production Market
8.1.1 US Viral Vector Production Market, by Type
8.1.2 US Viral Vector Production Market, by Indication
8.1.3 US Viral Vector Production Market, by Application
8.2 Canada Viral Vector Production Market
8.2.1 Canada Viral Vector Production Market, by Type
8.2.2 Canada Viral Vector Production Market, by Indication
8.2.3 Canada Viral Vector Production Market, by Application
8.3 Mexico Viral Vector Production Market
8.3.1 Mexico Viral Vector Production Market, by Type
8.3.2 Mexico Viral Vector Production Market, by Indication
8.3.3 Mexico Viral Vector Production Market, by Application
8.4 Rest of North America Viral Vector Production Market
8.4.1 Rest of North America Viral Vector Production Market, by Type
8.4.2 Rest of North America Viral Vector Production Market, by Indication
8.4.3 Rest of North America Viral Vector Production Market, by Application
Chapter 9. Company Profiles
9.1 Andelyn Biosciences, Inc.
9.1.1 Company Overview
9.1.2 Recent strategies and developments:
9.1.2.1 Partnerships, Collaborations, and Agreements:
9.1.2.2 Geographical Expansions:
9.2 Charles River Laboratories International, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Recent strategies and developments:
9.2.4.1 Product Launches and Product Expansions:
9.2.4.2 Acquisition and Mergers:
9.2.4.3 Geographical Expansions:
9.2.5 SWOT Analysis
9.3 Danaher Corporation
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 SWOT Analysis
9.4 FinVector Oy (Ferring Ventures S/A)
9.4.1 Company Overview
9.5 Thermo Fisher Scientific, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.5.5.2 Geographical Expansions:
9.5.6 SWOT Analysis
9.6 Novartis AG
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.6.5 SWOT Analysis
9.7 Takara Bio Inc. (Takara Holdings Inc.)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Avid Bioservices, Inc.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Recent strategies and developments:
9.8.3.1 Geographical Expansions:
9.9 Oxford Biomedica plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expenses
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Product Launches and Product Expansions:
9.10. Lonza Group Ltd.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 SWOT Analysis

Companies Mentioned

  • Andelyn Biosciences, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • FinVector Oy (Ferring Ventures S/A)
  • Thermo Fisher Scientific, Inc.
  • Novartis AG
  • Takara Bio Inc. (Takara Holdings Inc.)
  • Avid Bioservices, Inc.
  • Oxford Biomedica plc
  • Lonza Group Ltd.

Methodology

Loading
LOADING...